1027P 1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer

Abstract

This is a double-blind, randomised, Phase 3 study to compare efficacy, PK, and overall safety of candidate bevacizumab biosimilar CT-P16 and European Union-approved reference bevacizumab (BV), avastin®, in patients with metastatic or recurrent non-squamous non-small cell lung cancer (nsNSCLC). Here we report time-to-event analysis, including response duration (RD), time to progression (TTP), progression-free survival (PFS), and overall survival (OS), and safety analysis followed up to 1 year from enrollment of the last patient.